Values First Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Values First Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-579	Closed	-$58.6K	–	272
2023 Q1	$58.6K	Buy	+579	New	+$60.3K	0.04%	183
2021 Q2	–	Sell	-2,433	Closed	-$237K	–	154
2021 Q1	$237K	Buy	2,433 +20	+0.8%	+$2.1K	0.17%	129
2020 Q4	$231K	Buy	+2,413	New	+$233K	0.18%	134
2020 Q3	–	Sell	-1,881	Closed	-$230K	–	144
2020 Q2	$230K	Buy	+1,881	New	+$208K	0.23%	122
2020 Q1	–	Sell	-1,952	Closed	-$210K	–	138
2019 Q4	$210K	Buy	+1,952	New	+$204K	0.2%	118

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Values First Advisors's NBIX Position: Q2 2023 in Review

Values First Advisors sold out of Neurocrine Biosciences (NBIX) in Q2 2023, closing a stake of 579 shares — an estimated $58.6K sold.

Values First Advisors first reported a position in NBIX in Q4 2019 and held it in 5 quarters. The position peaked at $237K in Q1 2021. 456 funds tracked by Wall St. Rank hold NBIX as of Q2 2023.

Values First Advisors reported no remaining Neurocrine Biosciences position as of Q2 2023 after selling out during the quarter.
Values First Advisors sold 579 Neurocrine Biosciences shares in Q2 2023, an estimated $58.6K.
Values First Advisors first reported a position in Neurocrine Biosciences in Q4 2019 and held it in 5 quarters.
Values First Advisors's Neurocrine Biosciences position peaked at $237K in Q1 2021.
456 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2023.

Based on Values First Advisors's 13F filing for Q2 2023, filed 2 Aug 2023.